Taltz and Injection site warmth - a phase IV clinical study of FDA data

Summary:

We study 26,146 people who have side effects when taking Taltz. Injection site warmth is found, especially among people who are female, 40-49 old, have been taking the drug for < 1 month, also take Valtrex and have Psoriasis.

The phase IV clinical study analyzes which people take Taltz and have Injection site warmth. It is created by eHealthMe based on reports from the FDA, and is updated regularly. You may use the study as a second opinion to make health care decisions.

Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 700+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.

On Oct, 14, 2023

26,146 people reported to have side effects when taking Taltz.
Among them, 397 people (1.52%) have Injection site warmth.

What is Taltz?

Taltz has active ingredients of ixekizumab. Currently, eHealthMe is studying from 26,173 Taltz users.

What is Injection site warmth?

Injection site warmth is found to be associated with 1,064 drugs and 685 conditions by eHealthMe. Currently, we are studying 19,646 people who have Injection site warmth.

Number of Taltz and Injection site warmth reports submitted per year:

Could Taltz cause Injection site warmth?

* Approximation only. Some reports may have incomplete information.

Do you take Taltz and have Injection site warmth?

Check whether Injection site warmth is associated with a drug or a condition

How to use the study?

You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.

Related studies

Taltz side effects by duration, gender and age:

Taltz side effects (26,173 reports)

Injection site warmth treatments and more:

Injection site warmth (19,646 reports)

Common drugs associated with Injection site warmth:

All the drugs that are associated with Injection site warmth:

Injection site warmth (1,064 drugs)

Common conditions associated with Injection site warmth:

Rheumatoid arthritis: 6,942 reports
Psoriasis: 2,455 reports
Ankylosing spondylitis: 913 reports
Multiple sclerosis: 746 reports
Crohn's disease: 648 reports

All the conditions that are associated with Injection site warmth:

Injection site warmth (685 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on ixekizumab (the active ingredients of Taltz) and Taltz (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

Who is eHealthMe?

With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 700+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.